Crovalimab

可伐利单抗

Report date: 2026/03/16 20:01:47

Base Information

Drug NameCrovalimab
Drug Alias Name珂罗利单抗Crovalimab-akkz派圣凯PiaskyCH-7092230 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsAntiphospholipid SyndromeHemoglobinuria, ParoxysmalAnemia, Sickle Cell +[5] 
Global Approved IndicationsHemoglobinuria, Paroxysmal
Approved Indications in ChinaHemoglobinuria, Paroxysmal
Original Approved Country/TerritoryMainland China
Original Approved Date2024/02/06
Country/TerritoryCzechiaBelgiumCanada +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChugai Pharmaceutical Co LtdF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdRoche Pharma (Schweiz) AgF. Hoffmann-La Roche Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAnemia, Sickle CellAtypical Hemolytic Uremic Syndrome
Inactive IndicationsAntiphospholipid SyndromeGuillain-Barre Syndrome

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG